On STAT's podcast, hear about what happened with AbbVie's schizophrenia drug, Amgen's obesity drug and what might happen at ...

Pomp Investments investor Anthony Pompliano discusses the likelihood of a Bitcoin boom on 'The Claman Countdown.' The ...

AbbVie said on Monday that an experimental schizophrenia drug it gained through an $8.7 billion deal for Cerevel Therapeutics failed two mid-stage studies, sending the drugmaker's shares plunging 12.5 ...

Shares of AbbVie Inc. ABBV inched 0.60% higher to $201.68 Tuesday, on what proved to be an all-around great trading session ...

AbbVie has a lower P/E than the aggregate P/E of 112.06 of the Biotechnology industry. Ideally, one might believe that the ...

Pharmaceutical company AbbVie (ABBV) is the latest stock in my portfolio to announce a higher dividend. Accompanying its third-quarter earnings report, AbbVie declared a 5.8% increase in its ...

AbbVie announced Monday that it is buying Aliada Therapeutics, along with its lead drug candidate ALIA-1758 — an experimental antibody being tested for treating Alzheimer’s disease ...

The AbbVie Foundation has donated $75 million toward the construction of UChicago Medicine's $815 million freestanding cancer care pavilion in Hyde Park. When the 575,000-square-foot building ...

LATEST NEWS 07:15 Live News: Asian markets update; Fianna Fáil, Fine Gael and Sinn Féin’s housing plans rated 05:00 Comer brothers told to change plans for apartments next to Maynooth church 05:00 ...

October 28, 202410:12 PM UTCUpdated ago Oct 28 (Reuters) - U.S. drugmaker AbbVie (ABBV.N), opens new tab said on Monday it will buy Aliada Therapeutics for $1.4 billion in cash, betting on an ...

AbbVie has agreed to buy Aliada Therapeutics, a biotechnology company backed by Johnson & Johnson, for $1.4 billion in cash in a deal that adds a potential therapy for Alzheimer’s disease to ...